KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2025)

Rigel Pharmaceuticals (RIGL) has 7 years of Non-Current Debt data on record, last reported at $52.3 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 12.38% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $52.3 million, down 12.38%, while the annual FY2025 figure was $52.3 million, 12.38% down from the prior year.
  • Non-Current Debt reached $52.3 million in Q4 2025 per RIGL's latest filing, up from $30.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $59.8 million in Q3 2024 and bottomed at $19.8 million in Q1 2021.
  • Average Non-Current Debt over 5 years is $41.9 million, with a median of $42.2 million recorded in 2022.
  • Peak YoY movement for Non-Current Debt: surged 101.89% in 2021, then plummeted 49.85% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $19.9 million in 2021, then surged by 98.09% to $39.4 million in 2022, then skyrocketed by 32.76% to $52.4 million in 2023, then increased by 13.95% to $59.7 million in 2024, then decreased by 12.38% to $52.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $52.3 million in Q4 2025, $30.0 million in Q3 2025, and $37.5 million in Q2 2025.